DMRA

Damora Therapeutics, Inc. is a biotechnology company that focuses on hematologic disorders. It is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms (MPN), including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. Its lead asset, DMR-001, is an investigational monoclonal antibody therapy targeting mutant calreticulin (mutCALR). It is developing candidates for treatment of essential thrombocythemia (ET), an MPN associated with the overproduction of platelets, and myelofibrosis, an MPN involving the overproliferation of blood cells and deposition of fibrous material in the bone marrow and spleen. DMR-002, an afucosylated antibody designed to enhance antibody-dependent cellular cytotoxicity and amplify natural immune killing of malignant cells. DMR-003, a bi-specific T-cell engager antibody designed to recruit and direct T-cell-mediated killing of malignant cells.